Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy.

The Journal of clinical investigation - 1 May 2020

Li Jing, Wang Weichao, Zhang Yajia, Cieślik Marcin, Guo Jipeng, Tan Mengyao, Green Michael D, Wang Weimin, Lin Heng, Li Wei, Wei Shuang, Zhou Jiajia, Li Gaopeng, Jing Xiaojun, Vatan Linda, Zhao Lili, Bitler Benjamin, Zhang Rugang, Cho Kathleen R, Dou Yali, Kryczek Ilona, Chan Timothy A, Huntsman David, Chinnaiyan Arul M, Zou Weiping

Abstract excerpt

Whether mutations in cancer driver genes directly affect cancer immune phenotype and T cell immunity remains a standing question. ARID1A is a core member of the polymorphic BRG/BRM-associated factor chromatin remodeling complex. ARID1A mutations occur in human cancers and drive cancer development. Here, we studied the molecular, cellular, and clinical impact of ARID1A aberrations on cancer immunity. We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chromatin Assembly and Disassembly
Share to Enhancer of Zeste Homolog 2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunophenotyping

Share to Immunotherapy

Share to Interferons

Share to Lymphocytes, Tumor-Infiltrating

Share to Melanoma

Share to Tumor Escape

Source

Open in PubMed Open full text

Identifiers

PMID: 32027624
DOI: 10.1172/JCI134402
PMCID: PMC7190935

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy.PMID 32027624Read ↗

Effect and biomarker of immune checkpoint blockade therapy for ARID1A deficiency cancersSemantic proximity Read ↗

ARID1A suppresses R-loop-mediated STING-type I interferon pathway activation of anti-tumor immunity.Semantic proximity Read ↗

ARID1A and Its Impact Across the Hallmarks of CancerSemantic proximity Read ↗

ARID1A deficiency and immune checkpoint blockade therapy: From mechanisms to clinical applicationSemantic proximity Read ↗

ARID1A regulates DNA repair through chromatin organization and its deficiency triggers DNA damage-mediated anti-tumor immune responseSemantic proximity Read ↗

Pan-cancer analysis of ARID family members as novel biomarkers for immune checkpoint inhibitor therapy.Semantic proximity Read ↗

ARID1A mutation is associated with an immunosuppressive microenvironment and poor prognosis in hepatocellular carcinoma: An integrated bioinformatics analysis.Semantic proximity Read ↗

Low level of ARID1A contributes to adaptive immune resistance and sensitizes triple‐negative breast cancer to immune checkpoint inhibitorsSemantic proximity Read ↗

Comprehensive analysis of multiple parameters associated with tumor immune microenvironment in ARID1A mutant cancers.Semantic proximity Read ↗

ARID1A is a coactivator of STAT5 that contributes to CD8+ T cell dysfunction and anti-PD-1 resistance in gastric cancer.Semantic proximity Read ↗

ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade.Semantic proximity Read ↗

Impaired ARID1A expression attenuated the immune response in gastric cancer via histone acetylation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.